VANCOUVER,
Dec. 20, 2013 /PRNewswire/ - iCo
Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common
shares will begin trading today on OTCQX International, a segment
of the OTCQX marketplace in the U.S., under the symbol "ICOTF."
iCo's common shares will also continue to trade on the TSX Venture
Exchange under the symbol "ICO".
iCo expects to benefit from trading on OTCQX by
gaining greater exposure and increasing liquidity in the United States, the location of all
clinical sites for its ongoing Phase 2 iDEAL study for diabetic
macular edema (DME).
"We look forward to increasing awareness of the
Company's ongoing clinical developments and progress in
the United States, the single most
important biotechnology investor market globally, by trading on the
OTCQX marketplace," said Andrew Rae,
President & CEO of iCo Therapeutics.
OTCQX International, a segment of the OTCQX
marketplace, is reserved for high-quality non-U.S. companies that
are listed on a qualified international exchange and provide their
home country disclosure to U.S. investors. U.S. investors can
find current financial disclosures and Real-Time Level 2 quotes for
the company on www.otcmarkets.com.
Troutman Sanders LLP will serve as iCo
Therapeutics' Principal American Liaison ("PAL") on OTCQX,
responsible for providing professional guidance on OTCQX
requirements and U.S. federal securities laws.
About OTC Markets Group Inc.
OTC Markets Group Inc. operates Open, Transparent and Connected
financial marketplaces for 10,000 U.S. and global securities.
Through its OTC Link® ATS, they directly link a diverse network of
broker-dealers that provide liquidity and execution services for a
wide spectrum of securities. The company organizes these securities
into marketplaces to better inform investors of opportunities and
risks - OTCQX®, The Best Marketplace with Qualified Companies;
OTCQB®, The Venture Stage Marketplace with U.S. Reporting
Companies; and OTC Pink®, The Open Marketplace with Variable
Reporting Companies. OTC Markets Group's data-driven platform
enables investors to easily trade through the broker of their
choice at the best possible price and empowers a broad range of
companies to improve the quality and availability of information
for their investors. To learn more about OTC Markets Group,
visit www.otcmarkets.com.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates
or generics by employing reformulation and delivery technologies
for new or expanded use indications. The company has exclusive
worldwide rights to two drug candidates - iCo-007 for Diabetic
Macular Edema (DME) and iCo-008 for other sight-threatening
diseases. iCo-007 is in Phase 2 clinical studies for DME. With
Phase 2 clinical history, iCo-008 is targeted for the treatment of
keratoconjunctivitis and wet age-related macular degeneration. In
addition, iCo holds worldwide rights to an oral drug delivery
platform. The first platform candidate is the Oral Amp B Delivery
system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX
Venture Exchange under the symbol "ICO" and the OTCQX under the
symbol "ICOTF". For more information, visit the Company
website at: www.icotherapeutics.com.
No regulatory authority has approved or
disapproved the content of this release. The TSX Venture Exchange
does not accept responsibility for the adequacy or accuracy of this
release.
Forward Looking Statements
Certain statements included in this press release may be
considered forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan,"
"goal," "seek," "believe," "project," "estimate," "expect,"
"strategy," "future," "likely," "may," "should," "will," and
similar references to future periods. Such statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on
iCo's current beliefs as well as assumptions made by and
information currently available to iCo and relate to, among other
things, anticipated financial performance, business prospects,
strategies, regulatory developments, market acceptance and future
commitments. Readers are cautioned not to place undue reliance on
these forward-looking statements, which are based only on
information currently available to iCo and speak only as of the
date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo in its
public securities filings and on its website, actual events may
differ materially from current expectations. iCo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SOURCE iCo Therapeutics Inc.
